Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
WILMINGTON, Del., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of XBiotech Inc. (NASDAQ:XBIT)?
- Did you purchase your shares pursuant and/or traceable to the April 15, 2015 initial public offering, or between April 15, 2015 and November 23, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of XBiotech Inc. (“XBiotech” or the “Company”) (NASDAQ:XBIT) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Western District of Texas on behalf of all persons or entities that purchased the common stock of XBiotech between April 15, 2015 and November 23, 2015, inclusive (the “Class Period”) alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers. A separate complaint has been filed in the Superior Court of the State of California on behalf of all persons or entities that acquired XBiotech shares pursuant or traceable to its initial public offering (“IPO”) commenced on or about April 15, 2015, alleging violations of the Securities Exchange Act of 1933 against the Company and certain of its officers.
If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of XBiotech in the April 15, 2015 offering, or during the period April 15, 2015 and November 23, 2015, inclusive, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/xbiotech-inc-xbit.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
